NEW YORK (GenomeWeb News) – Epigenomics said today that it has signed two separate licensing agreements with molecular diagnostics firms DxS and OncoMethylome Sciences.
 
Under its cross-licensing deal with DxS, Epigenomics received worldwide, non-exclusive rights to DxS’ Scorpions technology for use in R&D and research kits. It also received an option to expand the license to include in vitro diagnostic applications.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.